688176.SH
亚虹医药-U
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 11.49
−5.82%Year over year
Reported trailing growth
- Revenue
- +20.5%
- EBITDA
- —
- EBIT
- -17.8%
- EPS
- -16.4%
- Free cash flow
- -9.4%
- Operating cash flow
- -4.9%
Forward estimates
Based on analyst estimates
- Revenue
- -66.4%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +2098.0%
- EBITDA
- -11.5%
- EBIT
- -11.6%
- Net income
- -8.4%
- EPS
- -8.8%
- Free cash flow
- -0.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026